Protara Therapeutics, Inc.
NASDAQ:TARA
5.17 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Protara Therapeutics, Inc. |
Symbool | TARA |
Munteenheid | USD |
Prijs | 5.17 |
Beurswaarde | 177,433,366 |
Dividendpercentage | 0% |
52-weken bereik | 1.595 - 10.48 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jesse Shefferman |
Website | https://www.protaratx.com |
An error occurred while fetching data.
Over Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)